

**RADIATION ONCOLOGY QUALITY ASSURANCE COMMITTEE**

CHELSEA HOTEL, TORONTO, ON  
 ROOM: WHISTLER  
 FRIDAY APRIL 27<sup>TH</sup>, 2018, 1:00 PM – 4:00 PM

CO-CHAIR: A. NICHOL  
 SENIOR INVESTIGATOR: W. PARULEKAR

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

- To interpret the priorities and goals of the CCTG Radiation Oncology Quality Assurance Committee.
- To become familiar with international efforts regarding radiation oncology quality assurance within the context of clinical trials.
- To describe Canadian led initiatives for quality radiotherapy.
- To become familiar with radiation oncology quality assurance needs and challenges in the conduct of clinical studies.
- To identify areas for research and publication within clinical trials conducted by CCTG and its collaborative partners.

<b>1:00 pm</b>	<b>Welcome</b>	<b>A. Nichol</b>
<b>Updates about ongoing studies with RTQA</b>		
<b>1:05 pm</b>	SBRT vs. conventional palliative radiotherapy for spinal metastases. <b>SC.24</b>	<b>Y. Lee</b>
<b>1:15 pm</b>	Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in BRAF Mutation–Positive Malignant Melanoma and brain metastases. <b>IND.224</b>	<b>Y. Lee</b>
<b>1:25 pm</b>	Phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer. <b>PR.19</b>	<b>G. Morton/E. Vigneault</b>
<b>1:35 pm</b>	Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver cancer. <b>HE.1</b>	<b>A. Nichol</b>

*Continued on next page...*

**RADIATION ONCOLOGY QUALITY ASSURANCE COMMITTEE**

**Protocols in development**

- |                |   |                           |
|----------------|---|---------------------------|
| <b>1:45 pm</b> | <b>TAILOR RT:</b> A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer <b>MA.39</b>  | <b>T. Whelan</b>          |
| <b>2:00 pm</b> | Randomized Phase II Study of Cisplatin + RT vs Durvalumab + RT followed by Maintenance Durvalumab vs Durvalumab plus RT followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Ca (LA-OSCC). <b>HN.9</b> | <b>K. Sultanem</b>        |
| <b>2:15 pm</b> | <b>EVADER:</b> Phase II trial of Elective Volume Adjusted De-Escalation RT in Patients with low-risk HPV-related oropharyngeal squamous cell ca <b>HN.10</b>  | <b>S. Bratman</b>         |
| <b>2:30 pm</b> | A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases <b>CE.7</b>  | <b>A. Nichol</b>          |
| <b>2:45 pm</b> | Phase 3 Trial of Local Ablative Therapy or Not for Hormone Sensitive Oligometastatic Prostate Cancer <b>PR.20</b>   | <b>P. Cheung/T. Niazi</b> |
| <b>3:00 pm</b> | <p><b>Activities of the ROQAC</b></p> <p><b>Update about ongoing ROQAC research efforts</b></p> <p style="padding-left: 40px;"><b>HE.1 Comparison of MIMs and EVOQ</b><br/> <b>Historical Review Alysa Fairchild, Alan Nichol, Srinivas Raman</b><br/> <b>HN.6 Automation of RTQA</b></p>   |                           |
| <b>3:50 pm</b> | <b>Other business</b>   | <b>A. Nichol</b>          |
| <b>4:00 pm</b> | <b>Meeting Adjourned</b>  |                           |